Market closedNon-fractional
Guardant Health/GH
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Guardant Health
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ticker
GH
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Providers and Services
Headquarters
Palo Alto, United States
Employees
1,774
Website
guardanthealth.com
Guardant Health Metrics
BasicAdvanced
$3.5B
Market cap
-
P/E ratio
-$3.95
EPS
0.92
Beta
-
Dividend rate
Price and volume
Market cap
$3.5B
Beta
0.92
Financial strength
Current ratio
5.948
Quick ratio
5.062
Long term debt to equity
1,932.369
Total debt to equity
1,973.31
Interest coverage (TTM)
-172.49%
Management effectiveness
Return on assets (TTM)
-17.29%
Return on equity (TTM)
-3,883.89%
Valuation
Price to revenue (TTM)
5.58
Price to book
51.65
Price to tangible book (TTM)
62.2
Price to free cash flow (TTM)
-11.21
Growth
Revenue change (TTM)
25.21%
Earnings per share change (TTM)
-39.21%
3-year revenue growth
26.55%
3-year earnings per share growth
5.25%
What the Analysts think about Guardant Health
Analyst Ratings
Majority rating from 22 analysts.
Guardant Health Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$168M
8.65%
Net income
-$115M
-38.56%
Profit margin
-68.23%
-43.44%
Guardant Health Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.67
-$0.73
-$1.58
-$0.94
-
Expected
-$1.17
-$0.94
-$0.86
-$0.85
-$0.76
Surprise
-42.65%
-22.67%
82.79%
10.35%
-
Guardant Health News
AllArticlesVideos
![Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer](https://cdn.snapi.dev/images/v1/b/i/press1-2461211.jpg)
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
Business Wire·4 weeks ago
![Guardant Health Named to TIME100 Most Influential Companies](https://cdn.snapi.dev/images/v1/n/z/press10-2455965.jpg)
Guardant Health Named to TIME100 Most Influential Companies
Business Wire·1 month ago
![Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening](https://cdn.snapi.dev/images/v1/r/i/conf14-2453525.jpg)
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Guardant Health stock?
Guardant Health (GH) has a market cap of $3.5B as of July 04, 2024.
What is the P/E ratio for Guardant Health stock?
The price to earnings (P/E) ratio for Guardant Health (GH) stock is 0 as of July 04, 2024.
Does Guardant Health stock pay dividends?
No, Guardant Health (GH) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Guardant Health dividend payment date?
Guardant Health (GH) stock does not pay dividends to its shareholders.
What is the beta indicator for Guardant Health?
Guardant Health (GH) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
![Buy or sell Guardant Health stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Guardant Health stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.